ATE476989T1 - Humanisierter monoklonaler antikörper gegen von- willebrand faktor - Google Patents

Humanisierter monoklonaler antikörper gegen von- willebrand faktor

Info

Publication number
ATE476989T1
ATE476989T1 AT99943621T AT99943621T ATE476989T1 AT E476989 T1 ATE476989 T1 AT E476989T1 AT 99943621 T AT99943621 T AT 99943621T AT 99943621 T AT99943621 T AT 99943621T AT E476989 T1 ATE476989 T1 AT E476989T1
Authority
AT
Austria
Prior art keywords
von willebrand
willebrand factor
monoclonal antibody
antibody against
humanized monoclonal
Prior art date
Application number
AT99943621T
Other languages
English (en)
Inventor
Man Co
Maximiliano Vasquez
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Application granted granted Critical
Publication of ATE476989T1 publication Critical patent/ATE476989T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99943621T 1998-08-19 1999-08-19 Humanisierter monoklonaler antikörper gegen von- willebrand faktor ATE476989T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/136,315 US6228360B1 (en) 1998-08-19 1998-08-19 Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
PCT/US1999/016724 WO2000010601A1 (en) 1998-08-19 1999-08-19 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody

Publications (1)

Publication Number Publication Date
ATE476989T1 true ATE476989T1 (de) 2010-08-15

Family

ID=22472317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99943621T ATE476989T1 (de) 1998-08-19 1999-08-19 Humanisierter monoklonaler antikörper gegen von- willebrand faktor

Country Status (17)

Country Link
US (4) US6228360B1 (de)
EP (1) EP1112085B1 (de)
JP (1) JP4590734B2 (de)
KR (1) KR100693260B1 (de)
CN (1) CN1259972C (de)
AT (1) ATE476989T1 (de)
AU (1) AU766500B2 (de)
BR (1) BR9913084A (de)
CA (1) CA2340466A1 (de)
DE (1) DE69942668D1 (de)
HU (1) HUP0103573A3 (de)
IL (2) IL141158A0 (de)
NO (1) NO20010747L (de)
NZ (1) NZ509536A (de)
RU (1) RU2223785C2 (de)
WO (1) WO2000010601A1 (de)
ZA (1) ZA200100939B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
GB0031448D0 (en) * 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
JP2005523882A (ja) * 2001-10-16 2005-08-11 アールエックスキネティックス，インコーポレイテッド 高濃度タンパク質製剤および製造の方法
JP2005298336A (ja) * 2002-01-29 2005-10-27 Ajinomoto Co Inc 炎症性疾患治療用薬剤
WO2004011030A1 (ja) * 2002-07-29 2004-02-05 Ajinomoto Co., Inc. 血小板減少症治療用医薬組成物
AU2003251238A1 (en) * 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
EP2284192A3 (de) 2002-11-08 2011-07-20 Ablynx N.V. Antikörper aus Camelidae zur sublingualen Verabreichung
AU2005222963B2 (en) * 2004-03-15 2009-10-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
RU2271010C2 (ru) * 2004-03-31 2006-02-27 Общество с ограниченной ответственностью "Фирма МонА" Способ иммуноферментного анализа для определения фактора виллебранда, моноклональное антитело к фактору виллебранда (варианты) и штамм гибридных культивируемых клеток животных mus. musculus l. - продуцент моноклональных антител к фактору виллебранда (варианты)
EP1755642B1 (de) * 2004-04-15 2010-01-13 Athera Biotechnologies Ab Annexin zur prävention von der ruptur des plaques
JP2008512098A (ja) * 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
WO2006046935A1 (en) * 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Methods of optimizing antibody variable region binding affinity
CA2593328C (en) * 2005-01-14 2018-02-06 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between von willebrand factor (vwf) and platelets
MX2007014564A (es) * 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
CA2718081A1 (en) * 2008-03-21 2009-09-24 Ablynx Nv Von willebrand factor specific binders and methods of use therefor
AU2010210535B2 (en) * 2009-02-06 2015-12-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102532316B (zh) * 2010-12-24 2014-06-18 神州细胞工程有限公司 一种抗vWF单克隆抗体及其应用
WO2015158851A1 (en) * 2014-04-16 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
DE69233482T2 (de) * 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
SG49597A1 (en) * 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
WO1993016185A2 (en) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
CA2149025A1 (en) * 1992-12-01 1994-06-09 Man Sung Co Humanized antibodies reactive with l-selectin
PT725655E (pt) * 1993-11-05 2004-01-30 Centocor Inc Utilizacao de compostos capazes de se ligar a glicoproteina gpiib/iiia para a prevencao de estenose e de restenose
ES2191702T3 (es) * 1994-03-17 2003-09-16 Merck Patent Gmbh Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
WO1996017078A1 (en) * 1994-11-30 1996-06-06 Ajinomoto Co., Inc. Antithrombotic agent and anti-von willebrand factor monoclonal antibodies
US6228360B1 (en) 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody

Also Published As

Publication number Publication date
DE69942668D1 (de) 2010-09-23
US20050197494A1 (en) 2005-09-08
US20030180293A1 (en) 2003-09-25
EP1112085A1 (de) 2001-07-04
NZ509536A (en) 2002-11-26
KR20010072749A (ko) 2001-07-31
JP4590734B2 (ja) 2010-12-01
HUP0103573A2 (hu) 2002-01-28
WO2000010601A1 (en) 2000-03-02
KR100693260B1 (ko) 2007-03-13
RU2223785C2 (ru) 2004-02-20
US6613328B2 (en) 2003-09-02
CN1259972C (zh) 2006-06-21
NO20010747L (no) 2001-04-03
US7138116B2 (en) 2006-11-21
US6228360B1 (en) 2001-05-08
AU5668099A (en) 2000-03-14
US7311913B2 (en) 2007-12-25
EP1112085B1 (de) 2010-08-11
US20030064068A1 (en) 2003-04-03
IL141158A0 (en) 2002-02-10
BR9913084A (pt) 2001-05-08
CN1311691A (zh) 2001-09-05
CA2340466A1 (en) 2000-03-02
ZA200100939B (en) 2001-09-03
HUP0103573A3 (en) 2003-09-29
NO20010747D0 (no) 2001-02-14
EP1112085A4 (de) 2002-11-20
IL141158A (en) 2006-04-10
AU766500B2 (en) 2003-10-16
JP2002523379A (ja) 2002-07-30

Similar Documents

Publication Publication Date Title
DE69942668D1 (de) Humanisierter monoklonaler antikörper gegen von-willebrand faktor
ES2187954T3 (es) Anticuerpos anti-integrina avb3 antagonistas.
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
DE69433406T2 (de) Antikörper gegen cd40
ES2184660T1 (es) Anticuerpos humanizados que secuestran peptidos abeta.
ATE361364T1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
FI964845A7 (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
FI963004L (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
FI956112A0 (fi) Monoklonaalinen anti- V-integriinivasta-aine
NO2006008I2 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
DK1308455T3 (da) Sammensætning omfattende anti-HER2-antistoffer
DE60235588D1 (de) Monoklonales Antikörper gegen das HCV Kernantigen
IT1271461B (it) Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
ATE248190T1 (de) Chemoattraktion-auslösender faktor aus lymphozyten und dessen verwendungen
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
BR0015872A (pt) Agentes antitrombóticos
FI20020807A0 (fi) Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
GR3030212T3 (en) Platelet activating factor antagonists.
FI20011055L (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
DE69020315D1 (de) Monoklonaler antikörper gegen c-reaktives protein.
EP1483292A4 (de) Mit bakteriellen collagen-bindenden proteinen kreuzreaktive monoklonale antikörper

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1112085

Country of ref document: EP